A Multiethnic Analysis of DNA Methylation Reveals Links Between Alzheimer's Disease and Metabolic Comorbidities
- 1University of North Texas Health Science Center
Abstract
BackgroundAlzheimers disease (AD) is the leading contributor to dementia burden, and the risk of developing it is impacted by a multitude of factors. Among these factors are metabolic conditions like type-2 diabetes (T2D) and metabolic syndrome (MetS), along with ethnicity, which interacts both with AD and the metabolic comorbidities. Previous studies have established associations between methylation patterns at specific CpG sites and risk for AD, T2D and MetS individually, but the underlying etiology that is responsible for interactions between metabolic conditions and AD risk remains unresolved.
ObjectiveWe aimed to examine methylation patterns among Mexican American (MA) and Non-Hispanic White (NHW) individuals in the context of AD, alongside T2D and MetS, to identify CpG sites associated with disease-specific and interaction-dependent methylation effects related to those comorbidities.
MethodsDNA methylation data from 551 patients of MA or NHW ancestry who were enrolled in the Texas Alzheimers Research and Care Consortium (TARCC) were available for analysis. Participants were stratified into groups by AD/T2D status or AD/MetS score and Beta-values from the Illumina MethylationEPIC chip array were obtained for each patient. Differential methylation status was analyzed using the lumi and cate packages in R.
ResultsFive CpG sites had statistically significant differential methylation patterns, including two (cg06322660 and cg25514677) which exhibited significant interactions between AD and T2D status or AD and MetS score respectively, with cg06322660 being significant in the NHW cohort and cg25514677 being significant in the MA cohort. The association at cg25514677 was replicated in an independent MA cohort.
ConclusionsThe two sites associated with interactions between AD and a metabolic condition could explain the influence that those conditions have on the risk for AD and are prime candidates for future study.
Related
- Trends and disparities in upper gastrointestinal cancer among patients with metabolic comorbidities: a retrospective CDC-WONDER analysis (1999–2020)
- Multivariate GWAS Analysis Reveals a Common Genetic Factor Linking Dry Eye Disease to Gastrointestinal Comorbidities
- Body mass index at diagnosis, postdiagnosis change, and role of metabolic comorbidities in relation to survival in nonmetastatic renal cell carcinoma patients.
- Integrated multi-omics reveals methylation-linked biological heterogeneity in intermediate-risk pediatric acute myeloid leukemia
- CO067 | ELUCIDATING THE EVIL RELATIONSHIP OF METABOLIC DYSFUNCTION–ASSOCIATED FATTY LIVER DISEASE WITH CARDIOVASCULAR COMORBIDITIES: THE COMPLEX INTERPLAY AMONG HYPERCOAGULABILITY, INFLAMMATION, AND LIVER FIBROSIS
BibTeX
@misc{landon2026multiethnic,
title = {{A Multiethnic Analysis of DNA Methylation Reveals Links Between Alzheimer's Disease and Metabolic Comorbidities}},
author = {B. Landon and A. Abraham Daniel and T. Fischer and N. Phillips and R. Barber and A. Reynolds and The Health and Aging Brain Study: Health Disparities (HABS-HD) Study Team},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.05.26364777},
url = {https://www.medrxiv.org/content/10.64898/2026.10.05.26364777v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - A Multiethnic Analysis of DNA Methylation Reveals Links Between Alzheimer's Disease and Metabolic Comorbidities
AU - B. Landon
AU - A. Abraham Daniel
AU - T. Fischer
AU - N. Phillips
AU - R. Barber
AU - A. Reynolds
AU - The Health and Aging Brain Study: Health Disparities (HABS-HD) Study Team
PY - 2026
DA - 2026/10/05
PB - medRxiv
DO - 10.64898/2026.10.05.26364777
UR - https://www.medrxiv.org/content/10.64898/2026.10.05.26364777v1
AB - BackgroundAlzheimers disease (AD) is the leading contributor to dementia burden, and the risk of developing it is impacted by a multitude of factors. Among these factors are metabolic conditions like type-2 diabetes (T2D) and metabolic syndrome (MetS), along with ethnicity, which interacts both with AD and the metabolic comorbidities. Previous studies have established associations between methylation patterns at specific CpG sites and risk for AD, T2D and MetS individually, but the underlying etiology that is responsible for interactions between metabolic conditions and AD risk remains unresolved. ObjectiveWe aimed to examine methylation patterns among Mexican American (MA) and Non-Hispanic White (NHW) individuals in the context of AD, alongside T2D and MetS, to identify CpG sites associated with disease-specific and interaction-dependent methylation effects related to those comorbidities. MethodsDNA methylation data from 551 patients of MA or NHW ancestry who were enrolled in the Texas Alzheimers Research and Care Consortium (TARCC) were available for analysis. Participants were stratified into groups by AD/T2D status or AD/MetS score and Beta-values from the Illumina MethylationEPIC chip array were obtained for each patient. Differential methylation status was analyzed using the lumi and cate packages in R. ResultsFive CpG sites had statistically significant differential methylation patterns, including two (cg06322660 and cg25514677) which exhibited significant interactions between AD and T2D status or AD and MetS score respectively, with cg06322660 being significant in the NHW cohort and cg25514677 being significant in the MA cohort. The association at cg25514677 was replicated in an independent MA cohort. ConclusionsThe two sites associated with interactions between AD and a metabolic condition could explain the influence that those conditions have on the risk for AD and are prime candidates for future study.
ER -